exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087944 RNA Name: hsa-miR-222-3p RNA Type: miRNA Chromosome: chrX Starnd: - Coordinate: Start Site(bp): 45747036 End Site(bp): 45747056 External Links: hsa-miR-222-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand CRKL chr22 20917407 20953747 + DNAJC14 chr12 55820960 55830824 - FOXP1 chr3 70952817 71583993 - KDSR chr18 63327726 63367228 - LRP6 chr12 12116025 12267044 - MPZL1 chr1 167721192 167791919 + NFIB chr9 14081843 14398983 - PALLD chr4 168497052 168928457 + TNPO1 chr5 72816312 72916733 + TUB chr11 8019244 8106112 + NME7 chr1 169132531 169367948 - PRPF40A chr2 152651593 152717997 - RIF1 chr2 151409883 151508013 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001247 chr22 46125304 46136418 + hsa_circ_0000670 chr16 9199043 9199243 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC020978.7 chr16 68224713 68227734 + AC022150.4 chr19 52650437 52653284 - ARHGAP27P1-BPTFP1-KPNA2P3 chr17 64749663 64781707 - GAS5 chr1 173858559 173868882 - NEAT1 chr11 65422774 65445540 + TUG1 chr22 30969245 30979395 + TYMSOS chr18 630886 658340 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.